Hemispherx BioPharma (NYSEAMERICAN:HEB) Executives Voluntarily Forgo 2024 Cash Bonuses

On December 19, 2024, Hemispherx BioPharma (NYSEAMERICAN:HEB) disclosed in an 8-K filing that executives Thomas K. Equels and Peter W. Rodino III have voluntarily decided to waive their entitlement to cash bonuses for the year 2024. This decision was communicated to the Compensation Committee of the Company’s Board of Directors as a means to assist […]

Leave a Reply

Your email address will not be published.

Previous post ‘The Seed of a Sacred Fig’ a powerful film made in secret
Next post Euronet Worldwide (NASDAQ:EEFT) Cut to Hold at StockNews.com